EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer

François-Clément Bidard iD, Erica L Mayer iD, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli iD, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Peter A Fasching, Adam Brufsky und 14 weitere

New England Journal of Medicine · 07.08.2025 · 393 (6) · 569-580

DOI: 10.1056/nejmoa2502929 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 07.08.2025. Verfasst von François-Clément Bidard und 25 weiteren Autor:innen. Beteiligte Einrichtung: Institut Curie, Paris and Saint-Cloud; INSERM Centre d'Investigation Clinique 1428, Paris; Versailles-Saint-Quentin University, Paris-Saclay Universi…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Estrogen Receptor alpha, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 212-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Camizestrant, a next-generation selective estrogen-receptor (ER) degrader and complete ER antagonist, has shown antitumor activity in ER-positive advanced breast cancer. METHODS: We tested patients with advanced breast cancer with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative tumors for ESR1 mutations in circulating tumor DNA (ctDNA) once every 2 to 3 months. All the patients had received at least 6 months of first-line therapy with an aromatase inhibitor plus a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib). Patients who were found to have an ESR1 mutation and did not have radiologic progression were assigned in a 1:1 ratio to switch to camizestrant (75 mg once daily) with a continued CDK4/6 inhibitor plus placebo in place of an aromatase inhibitor or to continue to receive an aromatase inhibitor plus a CDK4/6 inhibitor plus placebo in place of camizestrant. The primary outcome was investigator-assessed progression-free survival. RESULTS: A total of 3256 patients were tested for an ESR1 mutation. The 315 eligible patients were assigned to switch to camizestrant (157 patients) or to continue to receive an aromatase inhibitor (158 patients). At an interim analysis at a median follow-up of 12.6 months, the median progression-free survival was 16.0 months (95% confidence interval [CI], 12.7 to 18.2) in the camizestrant group and 9.2 months (95% CI, 7.2 to 9.5) in the aromatase-inhibitor group (hazard ratio for progression or death, 0.44; 95% CI, 0.31 to 0.60; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsEstrogen Receptor alphaAntineoplastic Agents, HormonalAdultAgedFemaleHumansMiddle AgedAromatase InhibitorsCirculating Tumor DNACyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6MutationProgression-Free SurvivalProtein Kinase InhibitorsFollow-Up StudiesAged, 80 and overBreast Neoplasms, MaleTreatment OutcomeBenzimidazolesAminopyridinesIsoquinolinesPiperazines

Substanzen

abemaciclibAromatase InhibitorsAZD9833Circulating Tumor DNACyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ESR1 protein, humanEstrogen Receptor alphapalbociclibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Institut Curie, Paris and Saint-Cloud; INSERM Centre d'Investigation Clinique 1428, Paris; Versailles-Saint-Quentin University, Paris-Saclay University, Saint Cloud, France.
  • Dana-Farber Cancer Institute, Boston.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Universitätsklinikum Ulm, Ulm, Germany.
  • Washington University School of Medicine, St. Louis.
  • Weill-Cornell Medicine, New York-Presbyterian Hospital, New York.

ORCID-Profile: François-Clément Bidard, Erica L Mayer, Massimo Cristofanilli, Javier Pascual

Förderung

  • AstraZeneca

Zitieren

APA

Bidard, F. C., Mayer, E. L., Park, Y. H., Janni, W., Ma, C., Cristofanilli, M., Bianchini, G., Kalinsky, K., Iwata, H., Chia, S., Fasching, P. A., Brufsky, A., Nowecki, Z., Pascual, J., Moreau, L., Chen, S. C., Karadurmus, N., Gal-Yam, E. N., Jung, K. H., …, & SERENA-6 Study Group (2025). First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. New England Journal of Medicine, 393(6), 569-580. https://doi.org/10.1056/nejmoa2502929

Vancouver

Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al. First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. New England Journal of Medicine. 2025;393(6):569-580. doi:10.1056/nejmoa2502929

BibTeX
@article{Bidard2025,
  author = {Bidard, François-Clément and Mayer, Erica L and Park, Yeon Hee and Janni, Wolfgang and Ma, Cynthia and Cristofanilli, Massimo and Bianchini, Giampaolo and Kalinsky, Kevin and Iwata, Hiroji and Chia, Stephen and Fasching, Peter A and Brufsky, Adam and Nowecki, Zbigniew and Pascual, Javier and Moreau, Lionel and Chen, Shin-Cheh and Karadurmus, Nuri and Gal-Yam, Einav Nili and Jung, Kyung Hae and Pernas, Sonia and McClain, Sasha and He, Wei and Klinowska, Teresa and Huang-Bartlett, Cynthia and Turner, Nicholas C and SERENA-6 Study Group, SERENA-6 Study Group},
  title = {First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {6},
  pages = {569--580},
  doi = {10.1056/nejmoa2502929}
}
Kostenlos starten →